52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved
Genentech
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.
Pharmaron-Beijing
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists ors1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.
University of Camerino
Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Westf£Lischen Wilhelms-Universit£T M£Nster
Some non-conventional biomolecular targets for diamidines. A short survey.
Xavier University of Louisiana
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
University of Strasburg
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.
Novartis Pharma
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Astrazeneca Pharmaceuticals
Assessment of structurally diverse philanthotoxin analogues for inhibitory activity on ionotropic glutamate receptor subtypes: discovery of nanomolar, nonselective, and use-dependent antagonists.
University of Copenhagen
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Friedrich-Schiller-Universitat Jena
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Merck Research Laboratories
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review.
University of Catania
Recent developments on synthesis and biological activities of ?-carboline.
Northwest A&F University
Design and synthesis of 6-methylpyridin-2-one derivatives as novel and potent GluN2A positive allosteric modulators for the treatment of cognitive impairment.
Takeda Pharmaceutical
Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Nanjing University of Chinese Medicine
Discovery of Pyrazolo[1,5-a]pyrazin-4-ones as Potent and Brain Penetrant GluN2A-Selective Positive Allosteric Modulators Reducing AMPA Receptor Binding Activity.
Takeda Pharmaceutical
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.
Central University of Punjab
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Central South University
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.
Indian Institute of Technology (Banaras Hindu University)
Evaluation of ?-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
University of Jena
Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors.
University Hospital Hradec Kralove
Orally efficacious NR2B-selective NMDA receptor antagonists.
Merck Research Laboratories
Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.
Parke-Davis Pharmaceutical Research
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.
Palack£
Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain.
University of Auckland
Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.
Jining Medical University
Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid-? peptide in Alzheimer's disease.
Alma Mater Studiorum - University of Bologna
Multi-target design strategies for the improved treatment of Alzheimer's disease.
China Pharmaceutical University
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
University of Bristol
A New Class of Potent N-Methyl-D-Aspartate Receptor Inhibitors: Sulfated Neuroactive Steroids with Lipophilic D-Ring Modifications.
Academy of Sciences of The Czech Republic V.V.I.
In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers.
Chiba University
Improving the inhibitory activity of arylidenaminoguanidine compounds at the N-methyl-D-aspartate receptor complex from a recursive computational-experimental structure-activity relationship study.
University of Kentucky
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists.
Glaxosmithkline Medicines Research Centre
Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
Chiba University
Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
Rugen Holdings (Cayman)
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
Rugen Holdings (Cayman)